Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alsevalimab (FPA150) in advanced solid tumors
NCT03514121Phase 1Terminated
- Sponsor
- Five Prime Therapeutics, Inc.
- Start
- Mar 2018
- Primary completion
- Apr 2021
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label trial of alsevalimab in solid tumor (advanced stage), breast cancer, ovarian cancer and 1 more, sponsored by Five Prime Therapeutics, Inc. Primary endpoints: Number of Participants Experiencing Grade 3 and Grade 4 Adverse Events, Number of Participants Experiencing Dose Limiting Toxicities up to 21 days and 1 more. Started Mar 2018; status: terminated.
02
Drugs
alsevalimab
03
Conditions
solid tumor (advanced stage)breast cancerovarian cancerendometrial cancer (EC)
Beyond the preview
Go deeper on NCT03514121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03514121.